Drugs / FluShield
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04484532 | Oct 2017 → Jun 2022 | acute myeloid leukemia, myelodysplastic syndrome | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT00769002 Comparator | Sep 2008 → Aug 2011 | influenza | Hackensack Meridian Health | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FluShield | “Flushield” NCT04484532 ↗ |
| Route | Intramuscular | “volunteers will receive a standard dose of i.m. TIV (FluShield)” NCT00769002 ↗ |